Fulgent Genetics (FLGT) Share-based Compensation (2015 - 2026)

Fulgent Genetics has disclosed Share-based Compensation across 12 years of filings, most recently posting $8.6 million for Q2 2026.

• In Q2 2026, Share-based Compensation fell 14.1% year-over-year to $8.6 million; the TTM figure through Jun 2026 stood at $37.5 million (down 10.52% YoY), while the FY2025 annual figure was $39.6 million, down 11.01% from the prior year.
• Share-based Compensation came in at $8.6 million for Q2 2026 at Fulgent Genetics, down from $9.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $11.6 million in Q2 2024 to a low of $5.6 million in Q1 2022.
• Average Share-based Compensation over 5 years is $9.9 million, with a median of $10.2 million recorded in 2023.
• The largest YoY upside for Share-based Compensation was 127.74% in 2022 against a maximum downside of 38.35% in 2022.
• Over 5 years, Share-based Compensation stood at $10.0 million in 2022, then rose by 14.07% to $11.4 million in 2023, then decreased by 8.96% to $10.4 million in 2024, then decreased by 10.88% to $9.3 million in 2025, then decreased by 7.03% to $8.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $8.6 million in Q2 2026, $9.9 million in Q1 2026, and $9.3 million in Q4 2025.